Protocol Details

A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	02-H-0250
Sponsoring Institute	National Heart, Lung and Blood Institute (NHLBI)
Recruitment Detail	Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 18 Max Age: 70
Referral Letter Required	No
Population Exclusion(s)	Children
Special Instructions	Currently Not Provided
Keywords	Cutaneous T Cell Lymphoma; Allogeneic PBSCT; Low Intensity Regimen
Recruitment Keyword(s)	Mycosis Fungoides; Sezary Syndrome; CTCL
Condition(s)	Mycosis Fungoides; Sezary Syndrome
Investigational Drug(s)	None
Investigational Device(s)	None
Intervention(s)	Drug: Campath-1H
Supporting Site	National Heart, Lung, and Blood Institute

This study will investigate the safety and effectiveness of a modified donor stem cell transplantation procedure for treating advanced mycosis fungoides (MF), a lymphoma primarily affecting the skin, and Sezary syndrome (SS), a leukemic form of the disease. Donated stem cells (cells produced by the bone marrow that mature into the different blood components-white cells, red cells and platelets) can cure patients with certain leukemias and lymphomas and multiple myeloma. These cells generate a completely new, functioning bone marrow. In addition, immune cells from the donor grow and generate a new immune system to help fight infections. The new immune cells also attack any residual tumor cells left in the body after intensive chemotherapy. However, stem cell transplantation carries a significant risk of death, because it requires completely suppressing the immune system with high-dose chemotherapy and radiation. In addition, lymphocytes from the donor may cause what is called graft vs. host disease (GvHD), in which these cells see the patient's cells as foreign and mount an immune response to destroy them. To try to reduce these risks, patients in this study will be given low-dose chemotherapy and no radiation, a regimen that is easier for the body to tolerate and involves a shorter period of complete immune suppression. In addition, a monoclonal antibody called Campath-1H will be given to target lymphocytes, including those that have become cancerous.

Patients with advanced MF or SS who are between 18 and 70 years of age and have a matched family donor 18 years of age or older may be eligible for this study. Candidates will have a medical history, physical examination and blood tests, lung and heart function tests, X-rays of the chest, eye examination, and bone marrow sampling (withdrawal through a needle of about a tablespoon of marrow from the hip bone), and small skin biopsy (surgical removal of a piece of tissue for microscopic examination) or needle biopsy of the tumor.

Stem cells will be collected from both the patient and donor. To do this, the hormone G-CSF will be injected under the skin for several days to push stem cells out of the bone marrow into the bloodstream. Then, the stem cells will be collected by apheresis. In this procedure the blood is drawn through a needle placed in one arm and pumped into a machine where the required cells are separated out and removed. The rest of the blood is returned through a needle in the other arm.

Before the transplant, a central venous line (large plastic tube) is placed into a major vein. This tube can stay in the body and be used the entire treatment period to deliver the donated stem cells, give medications, transfuse blood, if needed, and withdraw blood samples. Several days before the transplant procedure, patients will start a conditioning regimen of low-dose chemotherapy with Campath 1H, fludarabine, and, if necessary, cyclophosphamide. When the conditioning therapy is completed, the stem cells will be infused over a period of up to 4 hours. To help prevent rejection of donor cells and GvHD, cyclosporine and mycophenolate mofetil will be given by mouth or by vein for about 3 months starting 4 days before the transplantation.

The anticipated hospital stay is 3 to 4 days, when the first 3 doses of Campath will be monitored for drug side effects. The rest of the procedures, including the transplant, can be done on an outpatient basis. Follow-up visits for the first 3 months after the transplant will be scheduled once or twice a week for a physical examination, blood tests and symptoms check. Then, visits will be scheduled at 6, 12, 18, 24, 30, 36, and 48 months post-transplant. Visits for the first 3 years will include blood tests, skin biopsies, and bone marrow biopsies.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

RECIPIENT:

Ages 18-70 years (both inclusive)

Stages IIb to IVb patients with MF (biopsy diagnostic or consistent with MF) who have progressed despite at least one treatment regimen and all patients with SS

AND

Anticipated median survival less than 5 years or debilitation as a result of their disease.

No prior treatment for MF/SS within 30 days

HIV negative

ECOG performance status of 1 or less.

No major organ dysfunction precluding transplantation.

DLCO greater than or equal to 60 percent predicted

Left ventricular ejection fraction greater than or equal to 40 percent.

Less than 25 percent of liver involved with metastatic tumor by CT scan.

6/6 HLA matched family donor available

Ability to comprehend the investigational nature of the study and provide informed consent.

INCLUSION CRITERIA-DONOR:

6/6 HLA- matched family donor

Age greater than or equal to 18 years

Ability to comprehend the investigational nature of the study and provide informed consent.

EXCLUSION CRITERIA (ANY OF THE FOLLOWING)-RECIPIENT

Patient pregnant or lactating

Age greater than 70 or less than 18 years

ECOG performance status of 2 or more.

Psychiatric disorder or mental deficiency of the patient or donor sufficiently severe as to make compliance with the BMT treatment unlikely, and making informed consent impossible.

Major anticipated illness or organ failure incompatible with survival from BMT and where survival is considered insufficient to assess transplant outcome (i.e. less than 3 months).

DLCO less than 60 percent predicted

Left ventricular ejection fraction less than 40 percent

Serum creatinine greater than 2.0 mg/dl

Serum bilirubin greater than 4 mg/dl, transaminases greater than 5 times the upper limit of normal

HIV positive

History of other malignancies in the last five years with the exception of basal cell or squamous cell carcinoma of the skin

Disease which is not evaluable either clinically or radiographically

Evidence for CNS metastatic disease

Disease involving greater than 25 percent of the liver radiographically.

EXCLUSION CRITERIA (any of the following)-DONOR:

Donor pregnant or lactating

Age less than 18 years

HIV positive (donors who are positive for hepatitis B (HBV), hepatitis C (HCV) or human T-cell lymphotropic virus (HTLV-1) will be used at the discretion of the investigator following counseling and approval from the recipient).

Sickling hemoglobinopathy including HbSS or HbsC.

History of malignancy within 5 years except basal cell or squamous carcinoma of the skin.

Donor unfit to receive G-CSF and undergo apheresis (Uncontrolled hypertension, history of stroke, thrombocytopenia).

--Back to Top--

Citations:

Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM Primary cutaneous T-cell lymphoma: review and current conceptsJ Clin Oncol 2000 Aug;18(15):2908-25.

Diamandidou E, Cohen PR, Kurzrock R Mycosis fungoides and Sezary syndromeBlood 1996 Oct 1;88(7):2385-409.

Rook AH, Heald P The immunopathogenesis of cutaneous T-cell lymphomaHematol Oncol Clin North Am 1995 Oct;9(5):997-1010.

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information:
Ramaprasad Srinivasan, M.D. National Cancer Institute (NCI) National Institutes of Health Building 10 Room 3-5272 10 Center Drive Bethesda, Maryland 20892 (301) 496-6353 ramasrin@mail.nih.gov	Ramaprasad Srinivasan, M.D. National Cancer Institute (NCI) National Institutes of Health Building 10 Room 3-5272 10 Center Drive Bethesda, Maryland 20892 (301) 496-6353 ramasrin@mail.nih.gov	Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov

Clinical Trials Number:

NCT00047060

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

• Details on how to participate in a study
• Details on how to refer a patient to a study

NIH Clinical Studies Information Request

---

Contact the Office of Communications for:

• General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml

---

Contact the Department Clinical Research Informatics, (DCRI) for:

• Technical questions about Adobe Acrobat and the PDF format
• Technical questions about this web server

webmaster@cc.nih.gov